Nicotine Replacement Therapies

Phase 3Small molecule

Nicotine Replacement Therapies is one of 30 small molecule programs targeting Smoking Cessation. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Smoking CessationActive, not recruiting

Smoking CessationPhase 3

Active, not recruiting

Competition

Competitive Landscape

154 competitors in Smoking Cessation

#DrugCompanyPhaseTrials

Wellbutrin

GSK

Phase 3

5 2

Chantix

Pfizer

Phase 3

3 3

Ozempic

Novo Nordisk

Phase 3

2 4

Topamax

WWim Janssens

Phase 3

3 5

Rimonabant

Sanofi

Phase 3

5 6

Revia

Teva

Phase 2

2 7

Lopid

Pfizer

Phase 2

1 8

Pharmacotherapy

UUniversity of Pittsburgh

Phase 3

1 9

Standard Treatment

Boehringer Ingelheim

Phase 3

1 10

Pamelor

SSpecgx

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Smoking Cessation

NCT05154669

Clinical

Trials by Indication[1]

Smoking Cessation2 trials

Integrating Financial Coaching and Smoking Cessation Coaching

Recruiting·NNYU Langone Health·Phase 3·NCT05154669·488 enrolled

Effectiveness of Various Smoking Cessation Therapies in Reducing Smoking in Adolescents - 1

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00158171·128 enrolled

Buprenorphine1 trial

A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients

Completed·NNYU Langone Health·N/A·NCT02665208·203 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Nicotine Replacement Therapies. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nicotine Replacement Therapies compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nicotine Replacement Therapies. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NYU Langone Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNYU Langone Health

Nicotine Replacement Therapies

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Smoking Cessation2 trials

Buprenorphine1 trial

References

Drug Info

Quick Facts

Related News